Search Results 671-680 of 17355 for Break STD Taboo

1. Breast cancer - Doctors and departments - Mayo Clinic

   ... standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to ...

2. Breast cancer - Doctors and departments - Mayo Clinic

   ... standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to ...

3. Breast cancer - Doctors and departments - Mayo Clinic

   ... standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to ...

4. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

   ... standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make ...

5. Breast cancer - Doctors and departments - Mayo Clinic

   ... standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to ...

6. First In Human Study Of TUB-030 In Patients With Advanced Solid Tumors - Mayo Clinic

   In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the ...

7. A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make ...

8. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

   ... standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make ...

9. A Study of the Safety, Effectiveness and Tolerability of Nexvax-2 in Patients with Celiac Disease (CeD) - Mayo Clinic

   ... standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make ...

10. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

    ... standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make ...